ARYx Therapeutics, Inc.
ARYX · OTC
12/31/2009 | 12/31/2008 | 12/31/2007 | 12/31/2006 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.10 | 0.04 | 0.03 | 0.02 |
| FCF Yield | -39.86% | -83.39% | -38.69% | -62.76% |
| EV / EBITDA | -3.08 | -1.15 | -0.89 | 0.02 |
| Quality | ||||
| ROIC | 0.00% | 0.00% | -48.24% | -58.41% |
| Gross Margin | 0.00% | 98.82% | 93.70% | 55.35% |
| Cash Conversion Ratio | 1.05 | 1.45 | 1.01 | 0.15 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | 60.86% | – | – |
| Free Cash Flow Growth | 23.45% | -62.61% | -445.00% | 80.31% |
| Safety | ||||
| Net Debt / EBITDA | -0.15 | 0.73 | 1.76 | 0.32 |
| Interest Coverage | -15.56 | -15.78 | -21.30 | -21.37 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -3,860.82 | -1,907.19 | -115.73 |